Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 103

1.

THRB genetic polymorphisms can predict severe myelotoxicity after definitive chemoradiotherapy in patients with esophageal squamous cell carcinoma.

Miki I, Nakamura T, Kuwahara A, Yamamori M, Nishiguchi K, Tamura T, Okuno T, Omatsu H, Mizuno S, Hirai M, Azuma T, Sakaeda T.

Int J Med Sci. 2012;9(9):748-56. doi: 10.7150/ijms.5081. Epub 2012 Oct 23.

2.

VEGF G-1154A is predictive of severe acute toxicities during chemoradiotherapy for esophageal squamous cell carcinoma in Japanese patients.

Sakaeda T, Yamamori M, Kuwahara A, Hiroe S, Nakamura T, Okumura K, Okuno T, Miki I, Chayahara N, Okamura N, Tamura T.

Ther Drug Monit. 2008 Aug;30(4):497-503. doi: 10.1097/FTD.0b013e318180e3d2.

PMID:
18641541
3.

Genetic polymorphisms in SLC23A2 as predictive biomarkers of severe acute toxicities after treatment with a definitive 5-fluorouracil/cisplatin-based chemoradiotherapy in Japanese patients with esophageal squamous cell carcinoma.

Minegaki T, Kuwahara A, Yamamori M, Nakamura T, Okuno T, Miki I, Omatsu H, Tamura T, Hirai M, Azuma T, Sakaeda T, Nishiguchi K.

Int J Med Sci. 2014 Feb 7;11(4):321-6. doi: 10.7150/ijms.7654. eCollection 2014.

4.

VEGF -634C/G genotype is predictive of long-term survival after treatment with a definitive 5-fluorouracil/cisplatin-based chemoradiotherapy in Japanese patients with esophageal squamous cell carcinoma.

Tamura T, Kuwahara A, Yamamori M, Nishiguchi K, Nakamura T, Okuno T, Miki I, Manabe Y, Sakaeda T.

Int J Med Sci. 2012;9(10):833-7. doi: 10.7150/ijms.4914. Epub 2012 Nov 1.

5.

TNFRSF1B A1466G genotype is predictive of clinical efficacy after treatment with a definitive 5-fluorouracil/cisplatin-based chemoradiotherapy in Japanese patients with esophageal squamous cell carcinoma.

Kuwahara A, Yamamori M, Fujita M, Okuno T, Tamura T, Kadoyama K, Okamura N, Nakamura T, Sakaeda T.

J Exp Clin Cancer Res. 2010 Jul 20;29:100. doi: 10.1186/1756-9966-29-100.

6.

TNF-α -857C>T genotype is predictive of clinical response after treatment with definitive 5-fluorouracil/cisplatin-based chemoradiotherapy in Japanese patients with esophageal squamous cell carcinoma.

Omatsu H, Kuwahara A, Yamamori M, Fujita M, Okuno T, Miki I, Tamura T, Nishiguchi K, Okamura N, Nakamura T, Azuma T, Hirano T, Ozawa K, Hirai M.

Int J Med Sci. 2013 Oct 15;10(12):1755-60. doi: 10.7150/ijms.6749. eCollection 2013.

7.

Myelotoxicity of preoperative chemoradiotherapy is a significant determinant of poor prognosis in patients with T4 esophageal cancer.

Miyoshi N, Yano M, Takachi K, Kishi K, Noura S, Eguchi H, Yamada T, Miyashiro I, Ohue M, Ohigashi H, Sasaki Y, Ishikawa O, Doki Y, Imaoka S.

J Surg Oncol. 2009 Apr 1;99(5):302-6. doi: 10.1002/jso.21235.

PMID:
19170110
8.

Neoadjuvant concurrent chemoradiotherapy followed by definitive high-dose radiotherapy or surgery for operable thoracic esophageal carcinoma.

Murakami M, Kuroda Y, Okamoto Y, Kono K, Yoden E, Kusumi F, Hajiro K, Matsusue S, Takeda H.

Int J Radiat Oncol Biol Phys. 1998 Mar 15;40(5):1049-59.

PMID:
9539559
9.

[Phase II clinical trial of concurrent chemoradiotherapy (cisplatin plus 5-fluorouracil) for esophageal cancer].

Lin Q, Gao XS, Qiao XY, Chen K, Wang YD, Zhou ZG.

Ai Zheng. 2008 Oct;27(10):1077-81. Chinese.

PMID:
18851788
10.

Prognostic value of TP53 transcriptional activity on p21 and bax in patients with esophageal squamous cell carcinomas treated by definitive chemoradiotherapy.

Michel P, Magois K, Robert V, Chiron A, Lepessot F, Bodenant C, Roque I, Seng SK, Frebourg T, Paillot B.

Int J Radiat Oncol Biol Phys. 2002 Oct 1;54(2):379-85.

PMID:
12243811
11.

Late toxicity in complete response cases after definitive chemoradiotherapy for esophageal squamous cell carcinoma.

Kumekawa Y, Kaneko K, Ito H, Kurahashi T, Konishi K, Katagiri A, Yamamoto T, Kuwahara M, Kubota Y, Muramoto T, Mizutani Y, Imawari M.

J Gastroenterol. 2006 May;41(5):425-32.

PMID:
16799883
12.

Effects of plasma concentrations of 5-fluorouracil on long-term survival after treatment with a definitive 5-fluorouracil/cisplatin-based chemoradiotherapy in Japanese patients with esophageal squamous cell carcinoma.

Kuwahara A, Yamamori M, Kadoyama K, Nishiguchi K, Nakamura T, Miki I, Tamura T, Okuno T, Omatsu H, Sakaeda T.

J Exp Clin Cancer Res. 2011 Oct 5;30:94. doi: 10.1186/1756-9966-30-94.

13.
14.

Efficacy of concurrent chemoradiotherapy as a palliative treatment in stage IVB esophageal cancer patients with dysphagia.

Ikeda E, Kojima T, Kaneko K, Minashi K, Onozawa M, Nihei K, Fuse N, Yano T, Yoshino T, Tahara M, Doi T, Ohtsu A.

Jpn J Clin Oncol. 2011 Aug;41(8):964-72. doi: 10.1093/jjco/hyr088. Epub 2011 Jul 7.

PMID:
21742654
15.

Favorable genetic polymorphisms predictive of clinical outcome of chemoradiotherapy for stage II/III esophageal squamous cell carcinoma in Japanese.

Okuno T, Tamura T, Yamamori M, Chayahara N, Yamada T, Miki I, Okamura N, Kadowaki Y, Shirasaka D, Aoyama N, Nakamura T, Okumura K, Azuma T, Kasuga M, Sakaeda T.

Am J Clin Oncol. 2007 Jun;30(3):252-7.

PMID:
17551301
16.

[The association of XRCC2 gene polymorphism with susceptibility to esophageal squamous cell carcinoma and gastric cardiac adenocarcinoma in China].

Wang N, Dong XJ, Li Y, Guo W, Zhou RM, Zhang XJ, Wang SJ.

Zhonghua Yi Xue Yi Chuan Xue Za Zhi. 2007 Oct;24(5):538-43. Chinese.

PMID:
17922422
17.

Genetic variants of C1orf10 and risk of esophageal squamous cell carcinoma in a Chinese population.

Zhang W, Chen X, Luo A, Lin D, Tan W, Liu Z.

Cancer Sci. 2009 Sep;100(9):1695-700. doi: 10.1111/j.1349-7006.2009.01240.x. Epub 2009 Jun 1.

18.

A phase I trial of definitive chemoradiotherapy with docetaxel, cisplatin, and 5-fluorouracil (DCF-R) for advanced esophageal carcinoma: Kitasato digestive disease & oncology group trial (KDOG 0501).

Higuchi K, Koizumi W, Tanabe S, Sasaki T, Katada C, Ishiyama H, Hayakawa K.

Radiother Oncol. 2008 Jun;87(3):398-404. doi: 10.1016/j.radonc.2008.03.006. Epub 2008 Apr 9.

PMID:
18405987
19.

Concurrent chemoradiotherapy for locally advanced esophageal cancer--a pilot study by using daily low-dose cisplatin and continuous infusion of 5-fluorouracil.

Hsu CH, Yeh KH, Lui LT, Lee YC, Bu CF, Wang HP, Lin JT, Cheng AL.

Anticancer Res. 1999 Sep-Oct;19(5C):4463-7.

PMID:
10650793
20.

Phase II study of chemoradiotherapy with 5-fluorouracil and cisplatin for Stage II-III esophageal squamous cell carcinoma: JCOG trial (JCOG 9906).

Kato K, Muro K, Minashi K, Ohtsu A, Ishikura S, Boku N, Takiuchi H, Komatsu Y, Miyata Y, Fukuda H; Gastrointestinal Oncology Study Group of the Japan Clinical Oncology Group (JCOG).

Int J Radiat Oncol Biol Phys. 2011 Nov 1;81(3):684-90. doi: 10.1016/j.ijrobp.2010.06.033. Epub 2010 Oct 6.

PMID:
20932658

Supplemental Content

Support Center